Janux Therapeutics Inc (NASDAQ: JANX) open the trading on Thursday, with a bit cautious approach as it glided -5.02% to $46.50, before settling in for the price of $48.96 at the close. Taking a more long-term approach, JANX posted a 52-week range of $7.79-$65.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 32.66%. Meanwhile, its Annual Earning per share during the time was -92.62%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -4.86%. This publicly-traded company’s shares outstanding now amounts to $46.25 million, simultaneously with a float of $42.64 million. The organization now has a market capitalization sitting at $2.44 billion. At the time of writing, stock’s 50-day Moving Average stood at $50.06, while the 200-day Moving Average is $43.70.
Janux Therapeutics Inc (JANX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Janux Therapeutics Inc’s current insider ownership accounts for 18.75%, in contrast to 86.63% institutional ownership.
Janux Therapeutics Inc (JANX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
Janux Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -4.86% and is forecasted to reach -1.70 in the upcoming year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Let’s observe the current performance indicators for Janux Therapeutics Inc (JANX). It’s Quick Ratio in the last reported quarter now stands at 38.80. The Stock has managed to achieve an average true range (ATR) of 2.78. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 187.00.
In the same vein, JANX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.18, a figure that is expected to reach -0.39 in the next quarter, and analysts are predicting that it will be -1.70 at the market close of one year from today.
Technical Analysis of Janux Therapeutics Inc (JANX)
[Janux Therapeutics Inc, JANX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 16.14% While, its Average True Range was 2.74.
Raw Stochastic average of Janux Therapeutics Inc (JANX) in the period of the previous 100 days is set at 50.91%, which indicates a major rise in contrast to 4.54% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.68% that was lower than 53.05% volatility it exhibited in the past 100-days period.
